Abstract
1544P - The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have